JP6152107B2 - クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 - Google Patents

クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 Download PDF

Info

Publication number
JP6152107B2
JP6152107B2 JP2014530307A JP2014530307A JP6152107B2 JP 6152107 B2 JP6152107 B2 JP 6152107B2 JP 2014530307 A JP2014530307 A JP 2014530307A JP 2014530307 A JP2014530307 A JP 2014530307A JP 6152107 B2 JP6152107 B2 JP 6152107B2
Authority
JP
Japan
Prior art keywords
cdr
seq
antibody
sequence shown
tcda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014530307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501286A (ja
Inventor
ポール ハンフリーズ、デイヴィッド
ポール ハンフリーズ、デイヴィッド
ジョン ライトウッド、ダニエル
ジョン ライトウッド、ダニエル
ルイーズ タイソン、ケリー
ルイーズ タイソン、ケリー
エドワード オーモンド ナイト、デイヴィッド
エドワード オーモンド ナイト、デイヴィッド
ジャンニーヌ マデレーヌ エルヴェ、カリーヌ
ジャンニーヌ マデレーヌ エルヴェ、カリーヌ
エリザベス コンプソン、ジョアン
エリザベス コンプソン、ジョアン
ジョン ティモシー ペイジ、マシュー
ジョン ティモシー ペイジ、マシュー
チャールズ ペイン、アンドリュー
チャールズ ペイン、アンドリュー
ルイーズ フィッシャー、ニコラ
ルイーズ フィッシャー、ニコラ
マッケンジー、ブレンドン
コックス、マシュー
Original Assignee
ユセベ ファルマ ソシエテ アノニム
ユセベ ファルマ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46881094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6152107(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユセベ ファルマ ソシエテ アノニム, ユセベ ファルマ ソシエテ アノニム filed Critical ユセベ ファルマ ソシエテ アノニム
Publication of JP2015501286A publication Critical patent/JP2015501286A/ja
Application granted granted Critical
Publication of JP6152107B2 publication Critical patent/JP6152107B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014530307A 2011-09-16 2012-09-10 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体 Expired - Fee Related JP6152107B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535532P 2011-09-16 2011-09-16
US61/535,532 2011-09-16
US201261638731P 2012-04-26 2012-04-26
US61/638,731 2012-04-26
PCT/GB2012/052222 WO2013038156A1 (en) 2011-09-16 2012-09-10 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104698A Division JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Publications (2)

Publication Number Publication Date
JP2015501286A JP2015501286A (ja) 2015-01-15
JP6152107B2 true JP6152107B2 (ja) 2017-06-21

Family

ID=46881094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014530307A Expired - Fee Related JP6152107B2 (ja) 2011-09-16 2012-09-10 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2017104698A Expired - Fee Related JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2019187271A Ceased JP2020037555A (ja) 2011-09-16 2019-10-11 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017104698A Expired - Fee Related JP6603685B2 (ja) 2011-09-16 2017-05-26 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP2019187271A Ceased JP2020037555A (ja) 2011-09-16 2019-10-11 クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Country Status (30)

Country Link
US (2) US10752676B2 (OSRAM)
EP (2) EP2758432B1 (OSRAM)
JP (3) JP6152107B2 (OSRAM)
KR (1) KR20140063825A (OSRAM)
CN (2) CN103958544B (OSRAM)
AU (1) AU2012307157B2 (OSRAM)
BR (1) BR112014006175B1 (OSRAM)
CA (1) CA2848611A1 (OSRAM)
CL (1) CL2014000491A1 (OSRAM)
CO (1) CO6930310A2 (OSRAM)
CY (1) CY1121673T1 (OSRAM)
DK (1) DK2758432T3 (OSRAM)
EA (1) EA032475B1 (OSRAM)
EC (1) ECSP14013316A (OSRAM)
ES (1) ES2729278T3 (OSRAM)
HK (1) HK1199463A1 (OSRAM)
HR (1) HRP20190917T1 (OSRAM)
HU (1) HUE043661T2 (OSRAM)
IL (1) IL231167A0 (OSRAM)
LT (1) LT2758432T (OSRAM)
MX (1) MX2014002769A (OSRAM)
PE (1) PE20141547A1 (OSRAM)
PH (1) PH12014500456A1 (OSRAM)
PL (1) PL2758432T3 (OSRAM)
PT (1) PT2758432T (OSRAM)
SG (2) SG10201701055WA (OSRAM)
SI (1) SI2758432T1 (OSRAM)
TN (1) TN2014000101A1 (OSRAM)
WO (1) WO2013038156A1 (OSRAM)
ZA (1) ZA201402760B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020037555A (ja) * 2011-09-16 2020-03-12 ユセベ ファルマ ソシエテ アノニム クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
US9926345B2 (en) 2014-02-18 2018-03-27 The Hospital For Sick Children Compositions and methods for treating or preventing Clostridium infection
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
WO2016178773A1 (en) * 2015-04-06 2016-11-10 Saureus, Inc. System and method for detecting clostridium difficile toxins
CA2982358A1 (en) * 2015-04-15 2016-10-20 Medimmune, Llc Methods for treating clostridium difficile infection and associated disease
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN114057885A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
USD864160S1 (en) 2016-12-06 2019-10-22 Samsung Electronics Co., Ltd. Audio device
CN110088300A (zh) * 2016-12-14 2019-08-02 默沙东公司 与对靶向艰难梭菌毒素b的治疗的响应相关的人类遗传标志物
CN110607314B (zh) * 2019-10-31 2022-09-23 四川农业大学 一种TcdB RBD基因、重组RBD蛋白和应用
CN111763263A (zh) * 2020-07-09 2020-10-13 宁夏医科大学 一种艰难梭菌抗原及多克隆抗体的制备方法和检测试剂盒
CN112500484B (zh) * 2021-01-29 2021-06-08 迈杰转化医学研究(苏州)有限公司 一种抗trop2抗体及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
ES2149340T3 (es) 1993-11-17 2000-11-01 Om Pharma Disacaridos de glucosamina, metodo para su preparacion, composicion farmaceutica que los comprende, y su uso.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2003299527A1 (en) * 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
BR0215954A (pt) * 2002-11-26 2005-09-13 Uc Tech Métodos de redução da possibilidade de mortalidade em um animal, de expressão virulenta em um patógeno intestinal, e da expressão de adesina / lectina pa-i em uma célula bacteriana, de inibição de expressão de adesina / lectina pa-i em um patógeno intestinal, de ativação induzida por intestino de adesina / lectina pa-i, de mudança morfológica induzida por c4-hsl de um patógeno intestinal, e de aderência de célula bacteriana em um intestino de mamìfero, de melhoria de patogênese intestinal, de prevenção de uma doença ou condição anormal, de infecção de pele e respiratória, de uma doença sexualmente transmitida, de um distúrbio de trato digestivo, de perda de capacidade lactante em um animal, e de desenvolvimento de um distúrbio epitelial mediado por micróbio em uma animal de idade de amamentação, de irrigação de pelo menos uma porção do trato urinário, e para monitoração da administração de poli (etileno-glicol) (peg) a um animal, composição farmacêutica, kits para a prevenção ou tratamento terapêutico de sepsia derivada de intestino, e para a monitoração da administração de poli (etileno-glicol), e, preservativo
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0517592B1 (pt) 2004-12-27 2016-03-15 Huntsman Corp Australia Pty Ltd formulação agroquímica sólida, método para preparar a mesma, e, formulação de concentração de suspensão
AU2005321974B2 (en) 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CN101500581B (zh) * 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
US8697374B2 (en) * 2008-02-28 2014-04-15 3M Innovative Properties Company Antibodies to Clostridium difficile spores and uses thereof
KR102095257B1 (ko) * 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
WO2010094970A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
CN102947334B (zh) * 2010-04-15 2017-12-26 普罗杰尼克制药股份有限公司 用于治疗艰难梭菌相关感染和疾病的抗体
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US9815889B2 (en) * 2011-08-02 2017-11-14 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Antibodies for prevention and treatment of diseases caused by clostridium difficile
PT2758432T (pt) * 2011-09-16 2019-06-14 Ucb Biopharma Sprl Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
UA112203C2 (uk) * 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
US20150259402A1 (en) * 2012-10-19 2015-09-17 Evec Inc. Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) * 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
US9107906B1 (en) * 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020037555A (ja) * 2011-09-16 2020-03-12 ユセベ ファルマ ソシエテ アノニム クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体

Also Published As

Publication number Publication date
PT2758432T (pt) 2019-06-14
CN103958544A (zh) 2014-07-30
PE20141547A1 (es) 2014-10-25
WO2013038156A1 (en) 2013-03-21
BR112014006175B1 (pt) 2020-02-11
BR112014006175A2 (pt) 2017-04-04
CO6930310A2 (es) 2014-04-28
EP3617227A2 (en) 2020-03-04
CA2848611A1 (en) 2013-03-21
HK1199463A1 (en) 2015-07-03
KR20140063825A (ko) 2014-05-27
IL231167A0 (en) 2014-04-30
JP2020037555A (ja) 2020-03-12
PH12014500456A1 (en) 2014-04-14
HRP20190917T1 (hr) 2019-07-26
ECSP14013316A (es) 2014-08-29
JP2017149773A (ja) 2017-08-31
EP3617227A3 (en) 2020-06-03
AU2012307157A1 (en) 2014-04-24
PL2758432T3 (pl) 2019-08-30
EP2758432B1 (en) 2019-03-06
LT2758432T (lt) 2019-06-10
CL2014000491A1 (es) 2014-12-26
TN2014000101A1 (en) 2015-07-01
NZ623293A (en) 2016-05-27
AU2012307157B2 (en) 2017-08-03
CY1121673T1 (el) 2020-07-31
CN108424449A (zh) 2018-08-21
ZA201402760B (en) 2016-03-30
ES2729278T3 (es) 2019-10-31
US20200377578A1 (en) 2020-12-03
EA032475B1 (ru) 2019-06-28
DK2758432T3 (da) 2019-06-03
SG11201400193SA (en) 2014-05-29
SG10201701055WA (en) 2017-03-30
US10752676B2 (en) 2020-08-25
EA201400345A1 (ru) 2014-09-30
EP2758432A1 (en) 2014-07-30
MX2014002769A (es) 2014-06-11
US20140348844A1 (en) 2014-11-27
HUE043661T2 (hu) 2019-08-28
SI2758432T1 (sl) 2019-07-31
CN103958544B (zh) 2018-04-24
JP2015501286A (ja) 2015-01-15
JP6603685B2 (ja) 2019-11-06

Similar Documents

Publication Publication Date Title
JP6603685B2 (ja) クロストリジウム・ディフィシレの主要な外毒素ＴｃｄＡ及びＴｃｄＢに対する中和抗体
JP6159854B2 (ja) クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
ES2795667T3 (es) Composiciones para inhibir la activación del complemento dependiente de MASP-2
JP6022515B2 (ja) 抗ａ型インフルエンザウイルス中和抗体およびその使用
JP7724712B2 (ja) ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用
ES2689470T3 (es) Anticuerpos de Fab-Fv de conector único y métodos para producirlos
TW202005981A (zh) 高親和性、異構體選擇性之TGFβ1抑制劑及其用途
JP2017518958A (ja) 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
TW202019957A (zh) TGFβ1抑制劑及其用途
JP2013543382A (ja) 破骨細胞関連蛋白質Ｓｉｇｌｅｃ−１５を標的とした抗体
US20220169714A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
WO2020160022A1 (en) Compositions and methods for treatment of diseases involving cxcl1 function
NZ623293B2 (en) Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
WO2025213047A1 (en) Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170526

R150 Certificate of patent or registration of utility model

Ref document number: 6152107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees